Study of P97 Inhibitors in Mantle Cell Lymphoma

Rekha Rao, PhD
Published: Wednesday, Apr 05, 2017



Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

P97 is an ATPase that restores protein to homeostasis in cells and promotes retrotranslocation of misfolded proteins from the endoplasmic reticulum (ER), says Rao.

Researchers are working to target MCL with new agents that can induce ER stress. And when p97 function is inhibited, ER Rao adds, the ER becomes stressed, suggesting that p97 inhibitors could be effective the treatment of MCL.
 


Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).

P97 is an ATPase that restores protein to homeostasis in cells and promotes retrotranslocation of misfolded proteins from the endoplasmic reticulum (ER), says Rao.

Researchers are working to target MCL with new agents that can induce ER stress. And when p97 function is inhibited, ER Rao adds, the ER becomes stressed, suggesting that p97 inhibitors could be effective the treatment of MCL.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x